Subtype
Neuroblastoma
CI-CAN-00003408Explore in graph →
137 active trials3 approved drugs27 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003408Explore in graph →
Clinical trials
616 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (80)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04909515 | Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission. | withdrawn | Phase 2 | 0 | Y-mAbs TherapeuticsINDUSTRY | 4 | Sep 1, 2022 | clinicaltrials |
| NCT05303727 | Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma | not yet recruiting | Phase 2 | 64 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jul 1, 2022 |
| clinicaltrials |
| NCT02035137 | 131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat(N2011-01) | completed | Phase 2 | 114 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 2 | Jun 8, 2022 | clinicaltrials |
| NCT00072358 | Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma | completed | Phase 2 | 291 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 16, 2022 | clinicaltrials |
| NCT00567567 | Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma | completed | Phase 3 | 665 | Children's Oncology GroupNETWORK | 6 | Apr 28, 2022 | clinicaltrials |
| NCT02013336 | Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors | unknown | Phase 1 | 30 | South Plains Oncology ConsortiumNETWORK | 1 | Mar 31, 2022 | clinicaltrials |
| NCT02163356 | Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant Neuroblastoma(SPOC2013-001) | terminated | Phase 1 | 4 | South Plains Oncology ConsortiumNETWORK | 1 | Mar 31, 2022 | clinicaltrials |
| NCT02075177 | Expanded Access Study of Fenretinide Lym-X-Sorb Plus Ketoconazole in Neuroblastoma | no longer available | — | — | South Plains Oncology ConsortiumNETWORK | 1 | Mar 21, 2022 | clinicaltrials |
| NCT00492167 | Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma | completed | Phase 1 | 45 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 7, 2022 | clinicaltrials |
| NCT04049864 | DNA Vaccination Against Neuroblastoma | unknown | Early Phase 1 | 12 | Belarusian Research Center for Pediatric Oncology, Hematology and ImmunologyOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT02982941 | Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors | completed | Phase 1 | 25 | MacroGenicsINDUSTRY | 1 | Feb 8, 2022 | clinicaltrials |
| NCT05179850 | Computer Aided Diagnostic Tool on Computed Tomography Images for Diagnosis of Retroperitoneal Tumor in Children | unknown | — | 400 | West China HospitalOTHER | 1 | Jan 20, 2022 | clinicaltrials |
| NCT02452554 | Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma | completed | Phase 2 | 62 | Children's Oncology GroupNETWORK | 1 | Jan 13, 2022 | clinicaltrials |
| NCT03042416 | 18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety | completed | Phase 3 | 400 | University of AlbertaOTHER | 1 | Jan 10, 2022 | clinicaltrials |
| NCT03291080 | Oral Liquid 13-cis-retinoic Acid (13-CRA)(My-CRA) | completed | Phase 1 / Phase 2 | 20 | Nova Laboratories LimitedINDUSTRY | 1 | Oct 19, 2021 | clinicaltrials |
| NCT02743429 | Phase II Study of Monoclonal Antibody ch14.18/CHO Continuous Infusion in Patients With Primary Refractory or Relapsed Neuroblastoma | unknown | Phase 2 | 40 | University Medicine GreifswaldOTHER | 2 | Oct 4, 2021 | clinicaltrials |
| NCT01869725 | Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT | completed | Phase 2 | 68 | Sue O'DorisioOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT01619865 | Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors(GA-68) | completed | Phase 1 / Phase 2 | 223 | Sue O'DorisioOTHER | 1 | Jul 27, 2021 | clinicaltrials |
| NCT00499616 | Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma | completed | Phase 3 | 464 | Children's Oncology GroupNETWORK | 6 | Jul 6, 2021 | clinicaltrials |
| NCT02043899 | A Phase I/II Study of [124I]mIBG PET/CT in Neuroblastoma | completed | Phase 1 / Phase 2 | 36 | Cancer Research UKOTHER | 1 | Jun 21, 2021 | clinicaltrials |
| NCT01662804 | Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk Neuroblastoma and GD2-positive Solid Tumors | completed | Phase 1 | 14 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 27, 2021 | clinicaltrials |
| NCT01583842 | 124I-Metaiodobenzylguanidine (MIBG) PET/CT Diagnostic Imaging and Dosimetry for Patients With Neuroblastoma: A Pilot Study | terminated | Early Phase 1 | 10 | Miguel PampaloniOTHER | 1 | May 14, 2021 | clinicaltrials |
| NCT04864821 | Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor | unknown | Early Phase 1 | 24 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 0 | May 6, 2021 | clinicaltrials |
| NCT00536601 | High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors | completed | N/A | 174 | Roswell Park Cancer InstituteOTHER | 1 | Apr 22, 2021 | clinicaltrials |
| NCT00790413 | Haploidentical Stem Cell Transplantation in Neuroblastoma | unknown | Early Phase 1 | 15 | Lund University HospitalOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT02580136 | Esthesioneuroblastoma: Outcomes After Treatment(ENB) | withdrawn | — | 0 | Ricardo L. Carrau, MDOTHER | 1 | Feb 11, 2021 | clinicaltrials |
| NCT04017104 | Dynamic Whole Body Positron Emission Tomography/Computed Tomography Imaging | unknown | — | 60 | British Columbia Cancer AgencyOTHER | 1 | Jan 26, 2021 | clinicaltrials |
| NCT00202930 | Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma | terminated | Phase 2 | 4 | Jean M. Tersak, M.D.OTHER | 0 | Jan 22, 2021 | clinicaltrials |
| NCT02441062 | Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors | completed | Phase 2 | 122 | Sue O'DorisioOTHER | 1 | Dec 21, 2020 | clinicaltrials |
| NCT02159443 | Pretreatment Anti-Therapeutic Antibodies (PATA) in Patients Treated With hu14.18K322A Antibody | completed | — | 76 | St. Jude Children's Research HospitalOTHER | 1 | Nov 5, 2020 | clinicaltrials |
| NCT01987596 | Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer | terminated | Phase 3 | 23 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Oct 29, 2020 | clinicaltrials |
| NCT01704716 | High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN) | recruiting | Phase 3 | 3,300 | St. Anna KinderkrebsforschungOTHER | 20 | Oct 23, 2020 | clinicaltrials |
| NCT01704872 | ch14.18/CHO Bridging Study | completed | Phase 1 | 16 | St. Anna KinderkrebsforschungOTHER | 3 | Oct 22, 2020 | clinicaltrials |
| NCT00026780 | Eligibility Screening for a NCI Pediatric Oncology Branch Research Study | completed | — | 1,720 | National Cancer Institute (NCI)NIH | 1 | Oct 8, 2020 | clinicaltrials |
| NCT01467986 | Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma(RIST-rNB-2011) | completed | Phase 2 | 130 | University of RegensburgOTHER | 1 | Oct 6, 2020 | clinicaltrials |
| NCT00698009 | Haploidentical Natural Killer (NK) Cells in Patients With Relapsed or Refractory Neuroblastoma | terminated | Phase 2 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 24, 2020 | clinicaltrials |
| NCT01916187 | Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With Neuroblastoma | withdrawn | Phase 1 | 0 | NCIC Clinical Trials GroupNETWORK | 1 | Sep 21, 2020 | clinicaltrials |
| NCT01701479 | Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2)(LTI) | unknown | Phase 1 / Phase 2 | 288 | St. Anna KinderkrebsforschungOTHER | 7 | Jul 14, 2020 | clinicaltrials |
| NCT00939770 | Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma | completed | Phase 1 / Phase 2 | 122 | Children's Oncology GroupNETWORK | 2 | Jun 9, 2020 | clinicaltrials |
| NCT01331135 | Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors(Aflac ST0901) | completed | Phase 1 | 18 | Emory UniversityOTHER | 1 | May 29, 2020 | clinicaltrials |
| NCT01154816 | Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia | completed | Phase 2 | 118 | Children's Oncology GroupNETWORK | 2 | May 13, 2020 | clinicaltrials |
| NCT02390843 | Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors(AflacST1402) | completed | Phase 1 | 13 | Emory UniversityOTHER | 1 | Apr 3, 2020 | clinicaltrials |
| NCT00578864 | Protracted Etoposide During Induction Therapy for High Risk Neuroblastoma(PEPI) | completed | Phase 2 | 13 | Baylor College of MedicineOTHER | 1 | Mar 27, 2020 | clinicaltrials |
| NCT02786719 | High-Risk Neuroblastoma Chemotherapy Without G-CSF(SPRING) | completed | N/A | 13 | Baylor College of MedicineOTHER | 1 | Mar 12, 2020 | clinicaltrials |
| NCT02100930 | Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma | completed | N/A | 69 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 28, 2020 | clinicaltrials |
| NCT03545542 | Investigating the Microbiome and Volatile Organic Compound Profile of Children With Neuroblastoma | unknown | N/A | 20 | Medical University of GrazOTHER | 1 | Feb 25, 2020 | clinicaltrials |
| NCT00007813 | Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors | completed | Phase 1 | 21 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT01222780 | To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer | completed | Phase 1 | 22 | Acrotech Biopharma Inc.INDUSTRY | 1 | Jan 18, 2020 | clinicaltrials |
| NCT01962103 | Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 107 | CelgeneINDUSTRY | 7 | Dec 27, 2019 | clinicaltrials |
| NCT00428272 | HGS-ETR2 to Treat Children With Solid Tumors | terminated | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Sep 1, 2022source: clinicaltrials